Clinical trial
Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors
NCT00049088 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00049088 |
|---|---|
| Title | Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors |
| Official title | A Phase 1 Study of PS-341 in Combination With Docetaxel in Patients With Advanced Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological, Drug, Other |
| Interventions | docetaxel, bevacizumab, laboratory biomarker analysis, pharmacological study |
| Enrollment | 24 |
| Start date | Aug 1, 2002 |
| Primary completion | Feb 1, 2009 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: